Breast Cancer, Early Breast CancerPhase 3CAMBRIA-1NCT05774951

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

A Phase 3 study testing Camizestrant, Tamoxifen and Anastrozole in people with Breast Cancer, Early Breast Cancer, run by AstraZeneca at 709 sites in 39 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts

Official record

Search all trials

Trial summary

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy) and standard… Read more about this study

Who is it for?: Ages 18 to 130 years
Conditions the study is for: Breast Cancer, Early Breast Cancer
What is being tested?: Camizestrant, Tamoxifen and Anastrozole
Type of treatment: Pill or oral medicine
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 4,300 participants
Where: 709 sitesin 39 countries
Study dates: 31 Mar 2023to 29 May 2036
Phase: Phase 3

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 to 130 years
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

Women and Men, ≥18 years at the time of screening (or per national guidelines)
Histologically confirmed ER+/HER2- early-stage resected invasive breast cancer with high or intermediate risk of recurrence, based on clinical-pathological risk features, as defined in the protocol.
Completed adequate (definitive) locoregional therapy (surgery with or without radiotherapy) for the primary breast tumour(s), with or without (neo)adjuvant chemotherapy
Completed at least 2 years but no more than 5 years (+3 months) of adjuvant ET (+/- CDK4/6 inhibitor)
Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1
Adequate organ and marrow function

Who cannot join

Inoperable locally advanced or metastatic breast cancer
Pathological complete response following treatment with neoadjuvant therapy
History of any other cancer (except non-melanoma skin cancer or carcinoma in situ of the cervix or considered at very low risk of recurrence per investigator judgement) unless in complete remission with no therapy for a minimum of 5 years from the date of randomisation
Any evidence of severe or uncontrolled systemic diseases which, in the investigator's opinion precludes participation in the study or compliance
Known LVEF <50% with heart failure NYHA Grade ≥2.
Mean resting QTcF interval >480 ms at screening

Show all 11Show fewer

Concurrent exogenous sex hormone therapy
Any concurrent anti-cancer treatment not specified in the protocol with the exception of bisphosphonates (e.g. zoledronic acid) or RANKL inhibitors (eg, denosumab)
Previous treatment with camizestrant, investigational SERDs/investigational ER targeting agents, or fulvestrant
Currently pregnant (confirmed with positive serum pregnancy test) or breastfeeding
Patients with known hypersensitivity to active or inactive excipients of camizestrant or drugs with a similar chemical structure or class to camizestrant. In pre-/peri-menopausal female and male patients, known hypersensitivity or intolerance to LHRH agonists, that would preclude the patient from receiving any LHRH agonist

Trial locations and contacts

709 sites in 39 countries. Contact the study team or a site near you to ask about taking part.

AstraZeneca Clinical Study Information Center contact

1-877-240-9479

information.center@astrazeneca.com

AstraZeneca Breast Cancer Study Locator Service contact

1-877-400-4655

az-bcsl@careboxhealth.com

Country

City, postcode or hospital

Sites recruiting now only

709 sites in 39 countries

United States127 sites, 4 recruiting

Research Site
Aberdeen, South Dakota, 57401
Recruiting
Research Site
Anaheim, California, 92801
Active, not recruiting
Research Site
Anchorage, Alaska, 99508
Active, not recruiting
Research Site
Ann Arbor, Michigan, 48109
Active, not recruiting
Research Site
Appleton, Wisconsin, 54911
Withdrawn
Research Site
Atlanta, Georgia, 30310
Active, not recruiting
Research Site
Atlanta, Georgia, 30318
Active, not recruiting
Research Site
Aurora, Colorado, 80045
Withdrawn
Research Site
Austin, Texas, 78731
Withdrawn
Research Site
Baton Rouge, Louisiana, 70809
Active, not recruiting
Research Site
Belleville, New Jersey, 07109
Active, not recruiting
Research Site
Beverly Hills, California, 90211
Active, not recruiting
Research Site
Birmingham, Alabama, 35205
Active, not recruiting
Research Site
Boston, Massachusetts, 02111
Withdrawn
Research Site
Brewer, Maine, 04412
Withdrawn
Research Site
Chandler, Arizona, 85224
Active, not recruiting
Research Site
Charleston, West Virginia, 25304
Withdrawn
Research Site
Charlotte, North Carolina, 28204
Active, not recruiting
Research Site
Chattanooga, Tennessee, 37404
Active, not recruiting
Research Site
Chicago, Illinois, 60608
Withdrawn
Research Site
Chicago, Illinois, 60637
Active, not recruiting
Research Site
Cincinnati, Ohio, 45219
Withdrawn
Research Site
Cincinnati, Ohio, 45255
Active, not recruiting
Research Site
Clairton, Pennsylvania, 15025
Active, not recruiting
Research Site
Cleveland, Ohio, 44106
Active, not recruiting
Research Site
Cleveland, Ohio, 44195
Active, not recruiting
Research Site
Columbus, Georgia, 31904
Active, not recruiting
Research Site
Concord, California, 94520
Active, not recruiting
Research Site
Corona, California, 92882
Active, not recruiting
Research Site
Dallas, Texas, 75230
Active, not recruiting
Research Site
Decatur, Illinois, 62526
Active, not recruiting
Research Site
Denton, Texas, 76201
Active, not recruiting
Research Site
Detroit, Michigan, 48202
Active, not recruiting
Research Site
Dothan, Alabama, 36303
Active, not recruiting
Research Site
Durham, North Carolina, 27710-0001
Active, not recruiting
Research Site
East Lansing, Michigan, 48824
Active, not recruiting
Research Site
East Syracuse, New York, 13057
Active, not recruiting
Research Site
Elmhurst, Illinois, 60126
Active, not recruiting
Research Site
Fairfax, Virginia, 22031
Active, not recruiting
Research Site
Farmington, New Mexico, 87401
Active, not recruiting
Research Site
Fort Mitchell, Kentucky, 41017
Active, not recruiting
Research Site
Fort Myers, Florida, 33901
Active, not recruiting
Research Site
Fort Wayne, Indiana, 46804
Active, not recruiting
Research Site
Fountain Valley, California, 92708
Active, not recruiting
Research Site
Frederick, Maryland, 21702
Active, not recruiting
Research Site
Gainesville, Florida, 32603
Active, not recruiting
Research Site
Glenn Dale, Maryland, 20769
Active, not recruiting
Research Site
Greenbrae, California, 94904
Active, not recruiting
Research Site
Greensboro, North Carolina, 27403
Withdrawn
Research Site
Hartford, Connecticut, 06102
Active, not recruiting
Research Site
Hinsdale, Illinois, 60521
Active, not recruiting
Research Site
Honolulu, Hawaii, 96813
Withdrawn
Research Site
Hot Springs, Arkansas, 71913
Active, not recruiting
Research Site
Houston, Texas, 77024
Active, not recruiting
Research Site
Houston, Texas, 77030
Active, not recruiting
Research Site
Hyannis, Massachusetts, 02601
Active, not recruiting
Research Site
Independence, Missouri, 64057
Active, not recruiting
Research Site
Iowa City, Iowa, 52242
Active, not recruiting
Research Site
Irving, Texas, 75063
Recruiting
Research Site
Knoxville, Tennessee, 37920
Active, not recruiting
Research Site
Laconia, New Hampshire, 03246
Active, not recruiting
Research Site
Lancaster, South Carolina, 29720
Withdrawn
Research Site
Lansing, Michigan, 48910
Active, not recruiting
Research Site
Las Vegas, Nevada, 89148
Terminated
Research Site
Lexington, Kentucky, 40536
Active, not recruiting
Research Site
Lincoln, Nebraska, 68506
Active, not recruiting
Research Site
Los Alamitos, California, 90720
Active, not recruiting
Research Site
Louisville, Kentucky, 40202
Active, not recruiting
Research Site
Lynchburg, Virginia, 24501
Active, not recruiting
Research Site
Madison, Wisconsin, 53792
Active, not recruiting
Research Site
Miami Beach, Florida, 33140
Active, not recruiting
Research Site
Midlothian, Virginia, 23114
Active, not recruiting
Research Site
Milwaukee, Wisconsin, 53226
Active, not recruiting
Research Site
Mitchell, South Dakota, 57301
Active, not recruiting
Research Site
Morgantown, West Virginia, 26505
Active, not recruiting
Research Site
Nashville, Tennessee, 37203
Active, not recruiting
Research Site
Nashville, Tennessee, 37204
Active, not recruiting
Research Site
New Hyde Park, New York, 11042
Withdrawn
Research Site
New York, New York, 10011
Active, not recruiting
Research Site
New York, New York, 10019
Withdrawn
Research Site
New York, New York, 10029
Active, not recruiting
Research Site
Ogden, Utah, 84405
Active, not recruiting
Research Site
Orlando, Florida, 32806
Active, not recruiting
Research Site
Palo Alto, California, 94304
Active, not recruiting
Research Site
Park Ridge, Illinois, 60068
Terminated
Research Site
Park Ridge, Illinois, 60068
Active, not recruiting
Research Site
Philadelphia, Pennsylvania, 19106
Active, not recruiting
Research Site
Philadelphia, Pennsylvania, 19111
Active, not recruiting
Research Site
Pierre, South Dakota, 57501
Recruiting
Research Site
Pittsburgh, Pennsylvania, 15213
Active, not recruiting
Research Site
Plantation, Florida, 33324
Active, not recruiting
Research Site
Port Saint Lucie, Florida, 34952
Active, not recruiting
Research Site
Providence, Rhode Island, 02903
Active, not recruiting
Research Site
Raleigh, North Carolina, 27607
Active, not recruiting
Research Site
Reading, Pennsylvania, 19611
Active, not recruiting
Research Site
Reston, Virginia, 20190
Active, not recruiting
Research Site
Richmond, Virginia, 23235
Active, not recruiting
Research Site
Rocky Mount, North Carolina, 27804
Active, not recruiting
Research Site
Royal Oak, Michigan, 48073
Active, not recruiting
Research Site
Saint Augustine, Florida, 32086
Active, not recruiting
Research Site
Salt Lake City, Utah, 84106
Active, not recruiting
Research Site
San Diego, California, 92121
Active, not recruiting
Research Site
San Diego, California, 92123
Active, not recruiting
Research Site
Santa Fe, New Mexico, 87505
Active, not recruiting
Research Site
Scarborough, Maine, 04074
Withdrawn
Research Site
Seattle, Washington, 98101
Active, not recruiting
Research Site
Seattle, Washington, 98104
Active, not recruiting
Research Site
Silver Spring, Maryland, 20910
Active, not recruiting
Research Site
Sioux Falls, South Dakota, 57105
Active, not recruiting
Research Site
Spartanburg, South Carolina, 29303
Active, not recruiting
Research Site
Spokane, Washington, 99202
Active, not recruiting
Research Site
St. Petersburg, Florida, 33705
Active, not recruiting
Research Site
St. Petersburg, Florida, 33709
Active, not recruiting
Research Site
State College, Pennsylvania, 16803
Terminated
Research Site
Stony Brook, New York, 11794
Active, not recruiting
Research Site
Tacoma, Washington, 98405
Active, not recruiting
Research Site
Tallahassee, Florida, 32308
Active, not recruiting
Research Site
The Bronx, New York, 10461
Active, not recruiting
Research Site
Towson, Maryland, 21204
Active, not recruiting
Research Site
West Palm Beach, Florida, 33401
Active, not recruiting
Research Site
White Plains, New York, 10601
Active, not recruiting
Research Site
Whittier, California, 90603
Active, not recruiting
Research Site
Winston-Salem, North Carolina, 27103
Recruiting
Research Site
Winston-Salem, North Carolina, 27104
Active, not recruiting
Research Site
Winter Haven, Florida, 33880
Active, not recruiting
Research Site
Yankton, South Dakota, 57078
Active, not recruiting
Research Site
Youngstown, Ohio, 44504
Withdrawn

Other trials in United States

China66 sites

Research Site
Baoding, 071000
Active, not recruiting
Research Site
Beijing, 100005
Active, not recruiting
Research Site
Beijing, 100021
Withdrawn
Research Site
Beijing, 100044
Active, not recruiting
Research Site
Beijing, 100142
Active, not recruiting
Research Site
Beijing
Withdrawn
Research Site
Changchun, 130021
Active, not recruiting
Research Site
Changsha, 410008
Active, not recruiting
Research Site
Chengdu, 610000
Active, not recruiting
Research Site
Chengdu, 610041
Active, not recruiting
Research Site
Chengdu, 610072
Active, not recruiting
Research Site
Chifeng, 024000
Active, not recruiting
Research Site
Dalian, 116023
Active, not recruiting
Research Site
Foshan, 528000
Active, not recruiting
Research Site
Fuzhou, 350001
Withdrawn
Research Site
Fuzhou, 350011
Active, not recruiting
Research Site
Guangzhou, 510060
Active, not recruiting
Research Site
Guangzhou, 510120
Withdrawn
Research Site
Guangzhou, 510168
Withdrawn
Research Site
Haikou, 570102
Withdrawn
Research Site
Haikou, 570311
Active, not recruiting
Research Site
Hangzhou, 310003
Active, not recruiting
Research Site
Hangzhou, 310009
Active, not recruiting
Research Site
Hangzhou, 310020
Active, not recruiting
Research Site
Hangzhou, 310022
Active, not recruiting
Research Site
Harbin, 150081
Active, not recruiting
Research Site
Hefei, 230001
Active, not recruiting
Research Site
Hefei, 230012
Active, not recruiting
Research Site
Hefei, 230601
Active, not recruiting
Research Site
Hohhot, 010010
Active, not recruiting
Research Site
Huangpu District, 200025
Withdrawn
Research Site
Jinan, 2501117
Active, not recruiting
Research Site
Lanzhou, 730050
Active, not recruiting
Research Site
Liuzhou, 545005
Active, not recruiting
Research Site
Nanchang, 330009
Active, not recruiting
Research Site
Nanjing, 210009
Active, not recruiting
Research Site
Nanjing, 210029
Active, not recruiting
Research Site
Nanning, 530021
Withdrawn
Research Site
Nanning, 530021
Active, not recruiting
Research Site
Neijiang, 641000
Active, not recruiting
Research Site
Qingdao, 266100
Withdrawn
Research Site
Shanghai, 200032
Withdrawn
Research Site
Shanghai, 200032
Active, not recruiting
Research Site
Shanghai, 200127
Active, not recruiting
Research Site
Shantou, 515031
Withdrawn
Research Site
Shaoguan, 512027
Active, not recruiting
Research Site
Shenyang, 110001
Withdrawn
Research Site
Shenyang, 110016
Active, not recruiting
Research Site
Shijiazhuang, 050020
Active, not recruiting
Research Site
Suining, 629000
Active, not recruiting
Research Site
Suzhou, 215006
Active, not recruiting
Research Site
Taiyuan, 030000
Withdrawn
Research Site
Taizhou, 317000
Active, not recruiting
Research Site
Tianjin, 300060
Active, not recruiting
Research Site
Weifang, 261000
Active, not recruiting
Research Site
Wuhan, 430022
Active, not recruiting
Research Site
Wuhan, 430070
Active, not recruiting
Research Site
Wuhan, 430079
Active, not recruiting
Research Site
Xiangfan, 441021
Active, not recruiting
Research Site
Xining, 810001
Withdrawn
Research Site
Xinxiang, 453100
Active, not recruiting
Research Site
Xuzhou, 221000
Active, not recruiting
Research Site
Xuzhou, 221009
Active, not recruiting
Research Site
Yanji, 133000
Active, not recruiting
Research Site
Yantai, 264000
Active, not recruiting
Research Site
Zhengzhou, 450052
Active, not recruiting

Other trials in China

Spain44 sites

Research Site
A Coruña, 15006
Active, not recruiting
Research Site
A Coruña, 15009
Active, not recruiting
Research Site
Albacete, 02006
Active, not recruiting
Research Site
Alcoy, 3804
Active, not recruiting
Research Site
Alicante, 3015
Active, not recruiting
Research Site
Alzira, 46600
Active, not recruiting
Research Site
Badajoz, 06080
Active, not recruiting
Research Site
Badalona, 08003
Active, not recruiting
Research Site
Badalona, 08916
Active, not recruiting
Research Site
Barakaldo, 48903
Active, not recruiting
Research Site
Barcelona, 08028
Active, not recruiting
Research Site
Barcelona, 08036
Active, not recruiting
Research Site
Barcelona, 8035
Active, not recruiting
Research Site
Cáceres, 10003
Active, not recruiting
Research Site
Elche(Alicante), 03202
Active, not recruiting
Research Site
Galdakao, 48960
Active, not recruiting
Research Site
Girona, 17007
Active, not recruiting
Research Site
Granada, 18007
Active, not recruiting
Research Site
Granada, 18014
Active, not recruiting
Research Site
Jerez de La Frontera (Cádiz), 11407
Active, not recruiting
Research Site
L'Hospitalet de Llobregat, 08908
Active, not recruiting
Research Site
Leganés, 28911
Active, not recruiting
Research Site
Lleida, 25198
Active, not recruiting
Research Site
Madrid, 28033
Active, not recruiting
Research Site
Madrid, 28040
Active, not recruiting
Research Site
Madrid, 28050
Active, not recruiting
Research Site
Majadahonda, 28222
Active, not recruiting
Research Site
Manresa, 8242
Active, not recruiting
Research Site
Murcia, 30008
Active, not recruiting
Research Site
Oviedo, 33011
Active, not recruiting
Research Site
Parla, 28981
Active, not recruiting
Research Site
Port de Sagunt, 46520
Active, not recruiting
Research Site
Reus, 43204
Active, not recruiting
Research Site
Salamanca, 37007
Active, not recruiting
Research Site
San Sebastián, 20014
Active, not recruiting
Research Site
Sant Joan d'Alacant, 03550
Withdrawn
Research Site
Santander, 39008
Active, not recruiting
Research Site
Seville, 41009
Active, not recruiting
Research Site
Seville, 41013
Active, not recruiting
Research Site
Teruel, 44001
Terminated
Research Site
Toledo, 45007
Withdrawn
Research Site
Valencia, 46009
Active, not recruiting
Research Site
Valencia, 46015
Active, not recruiting
Research Site
Valencia, 46017
Active, not recruiting

Other trials in Spain

Brazil37 sites, 4 recruiting

Research Site
Alfenas, 37130-000
Active, not recruiting
Research Site
Belo Horizonte, 30130-100
Active, not recruiting
Research Site
Belo Horizonte, 30150-274
Active, not recruiting
Research Site
Brasília, 70390-700
Withdrawn
Research Site
Brasília, 71681-603
Active, not recruiting
Research Site
Chapecó, 89812-220
Active, not recruiting
Research Site
Cuiabá, 78040-400
Terminated
Research Site
Curitiba, 80810-050
Active, not recruiting
Research Site
Curitiba, 81520-060
Recruiting
Research Site
Fortaleza, 60170-170
Active, not recruiting
Research Site
Fortaleza, 60430-230
Active, not recruiting
Research Site
Lajeado, 95900000
Active, not recruiting
Research Site
Londrina, 86015-520
Recruiting
Research Site
Natal, 59075-740
Active, not recruiting
Research Site
Niterói, 24020-096
Active, not recruiting
Research Site
Piracicaba, 13419-155
Active, not recruiting
Research Site
Porto Alegre, 90035-001
Active, not recruiting
Research Site
Porto Alegre, 90035-903
Active, not recruiting
Research Site
Porto Alegre, 90050-170
Active, not recruiting
Research Site
Porto Alegre, 90880-480
Active, not recruiting
Research Site
Pouso Alegre, 37554-216
Active, not recruiting
Research Site
Recife, 50070-070
Active, not recruiting
Research Site
Ribeirão Preto, 14051-140
Active, not recruiting
Research Site
Rio de Janeiro, 20560-120
Active, not recruiting
Research Site
Rio de Janeiro, 22250-905
Active, not recruiting
Research Site
Rio de Janeiro, 22290-160
Recruiting
Research Site
Salvador, 40110-060
Withdrawn
Research Site
Salvador, 41253-190
Active, not recruiting
Research Site
São Paulo, 01236-030
Active, not recruiting
Research Site
São Paulo, 01317-001
Active, not recruiting
Research Site
São Paulo, 01323-001
Active, not recruiting
Research Site
São Paulo, 01508-010
Active, not recruiting
Research Site
São Paulo, 01509-900
Active, not recruiting
Research Site
São Paulo, 08270-070
Active, not recruiting
Research Site
Taubaté, 12030-200
Recruiting
Research Site
Três Lagoas, 79601-001
Active, not recruiting
Research Site
Vitória, 29055-450
Active, not recruiting

Other trials in Brazil

Germany35 sites, 27 recruiting

Research Site
Aachen, 52074
Recruiting
Research Site
Augsburg, 86150
Recruiting
Research Site
Bayreuth, 95445
Withdrawn
Research Site
Berlin, 10317
Recruiting
Research Site
Berlin, 12623
Recruiting
Research Site
Bonn, 53111
Recruiting
Research Site
Deggendorf, 94469
Withdrawn
Research Site
Dessau, 6847
Recruiting
Research Site
Dresden, 01307
Recruiting
Research Site
Düsseldorf, 40225
Recruiting
Research Site
Düsseldorf, 40235
Recruiting
Research Site
Eggenfelden, 84307
Recruiting
Research Site
Esslingen am Neckar, 73730
Recruiting
Research Site
Georgsmarienhütte, 49124
Recruiting
Research Site
Gütersloh, 33332
Recruiting
Research Site
Hamburg, 20259
Recruiting
Research Site
Hamburg, 21073
Recruiting
Research Site
Heidelberg, 69120
Recruiting
Research Site
Kiel, 24105
Withdrawn
Research Site
Landshut, 84036
Recruiting
Research Site
Lübeck, 23562
Withdrawn
Research Site
Mainz, 55131
Withdrawn
Research Site
Memmingen, 87700
Recruiting
Research Site
München, 80637
Recruiting
Research Site
Ravensburg, 88212
Recruiting
Research Site
Rüsselsheim am Main, 65428
Recruiting
Research Site
Stralsund, 18439
Recruiting
Research Site
Torgau, 4860
Recruiting
Research Site
Trier, 54290
Recruiting
Research Site
Ulm, 89075
Withdrawn
Research Site
Velbert, 42551
Withdrawn
Research Site
Wiesbaden, 65189
Withdrawn
Research Site
Wiesbaden, 65199
Recruiting
Research Site
Worms, 67550
Recruiting
Research Site
Wuppertal, 42283
Recruiting

Other trials in Germany

France34 sites

Research Site
Angers, 49055
Withdrawn
Research Site
Argenteuil, 95100
Active, not recruiting
Research Site
Avignon, 84918
Active, not recruiting
Research Site
Bordeaux, 33000
Active, not recruiting
Research Site
Bordeaux, 33077
Active, not recruiting
Research Site
Bourg-en-Bresse, 01012
Withdrawn
Research Site
Caen, 14076
Active, not recruiting
Research Site
Cholet, 49300
Active, not recruiting
Research Site
Clermont-Ferrand, 63011
Withdrawn
Research Site
Dijon, 21079
Withdrawn
Research Site
Epagny Metz-Tessy, 74370
Withdrawn
Research Site
Lille, 59000
Active, not recruiting
Research Site
Lorient, 56322
Active, not recruiting
Research Site
Lyon, 69008
Active, not recruiting
Research Site
Marseille, 13273
Active, not recruiting
Research Site
Metz, 57085
Active, not recruiting
Research Site
Montpellier, 34070
Active, not recruiting
Research Site
Montpellier, 34298
Active, not recruiting
Research Site
Nantes, 44202
Active, not recruiting
Research Site
Nîmes, 30029
Active, not recruiting
Research Site
Paris, 75010
Withdrawn
Research Site
Paris, 75013
Active, not recruiting
Research Site
Pierre-Bénite, 69310
Active, not recruiting
Research Site
Plerin SUR MER, 22190
Active, not recruiting
Research Site
Poitiers, 86021
Active, not recruiting
Research Site
Quimper, 29107
Active, not recruiting
Research Site
Rennes, 35042
Withdrawn
Research Site
Saint-Cloud, 92210
Withdrawn
Research Site
Saint-Herblain, 44805
Withdrawn
Research Site
Saint-Priest-en-Jarez, 42270
Active, not recruiting
Research Site
Suresnes, 92151
Active, not recruiting
Research Site
Toulouse, 31059
Active, not recruiting
Research Site
Tours, 37044
Active, not recruiting
Research Site
Villejuif, 94805
Active, not recruiting

Other trials in France

Japan34 sites

Research Site
Chiba, 260-8717
Active, not recruiting
Research Site
Chūōku, 104-8560
Active, not recruiting
Research Site
Fukuoka, 811-1395
Active, not recruiting
Research Site
Fukushima, 960-1295
Active, not recruiting
Research Site
Hidaka-shi, 350-1298
Active, not recruiting
Research Site
Hirakata-shi, 573-1191
Active, not recruiting
Research Site
Hiroshima, 730-0011
Active, not recruiting
Research Site
Isehara-shi, 259-1193
Active, not recruiting
Research Site
Kagoshima, 892-0833
Active, not recruiting
Research Site
Kashiwa, 227-8577
Active, not recruiting
Research Site
Kitaadachi-gun, 362-0806
Active, not recruiting
Research Site
Kōtoku, 135-8550
Active, not recruiting
Research Site
Kumamoto, 860-8556
Active, not recruiting
Research Site
Kurume-shi, 830-0013
Active, not recruiting
Research Site
Kyoto, 606-8507
Active, not recruiting
Research Site
Matsuyama, 791-0280
Active, not recruiting
Research Site
Nagoya, 464-8681
Active, not recruiting
Research Site
Nagoya, 466-8560
Active, not recruiting
Research Site
Nagoya, 467-0001
Active, not recruiting
Research Site
Niigata, 951-8566
Active, not recruiting
Research Site
Ōita, 870-8511
Active, not recruiting
Research Site
Osaka, 533-0024
Active, not recruiting
Research Site
Osaka, 540-0006
Active, not recruiting
Research Site
Osaka, 541-8567
Active, not recruiting
Research Site
Ota-shi, 373-8550
Active, not recruiting
Research Site
Sagamihara-shi, 252-0375
Active, not recruiting
Research Site
Sapporo, 060-8648
Active, not recruiting
Research Site
Sendai, 980-8574
Active, not recruiting
Research Site
Shinagawa-ku, 142-8666
Active, not recruiting
Research Site
Suita-shi, 565-0871
Active, not recruiting
Research Site
Sunto-gun, 411-8777
Active, not recruiting
Research Site
Takasaki-shi, 370-0829
Active, not recruiting
Research Site
Tsu, 514-8507
Active, not recruiting
Research Site
Yokohama, 241-8515
Active, not recruiting

Other trials in Japan

India18 sites

Research Site
Bangalore, 560027
Terminated
Research Site
Bangalore, 560076
Withdrawn
Research Site
Belagavi, 590010
Withdrawn
Research Site
Bhubaneswar, 751019
Withdrawn
Research Site
Hubli, 580029
Active, not recruiting
Research Site
Hyderabad, 500082
Withdrawn
Research Site
Jaipur, 302017
Withdrawn
Research Site
Kolkata, 700020
Active, not recruiting
Research Site
Mumbai, 400 012
Active, not recruiting
Research Site
Nagpur, 440026
Withdrawn
Research Site
Nashik, 422005
Active, not recruiting
Research Site
New Delhi, 110 085
Active, not recruiting
Research Site
New Delhi, 110005
Withdrawn
Research Site
New Delhi, 110076
Withdrawn
Research Site
Pune, 411004
Withdrawn
Research Site
Thane, 401107
Withdrawn
Research Site
Visakhapatnam, 530040
Active, not recruiting
Research Site
West Bengal, 700 156
Terminated

Other trials in India

Argentina16 sites

Research Site
Buenos Aires, C1430EGF
Withdrawn
Research Site
CABA, C1119ACN
Active, not recruiting
Research Site
Capital Federal, C1417DTB
Active, not recruiting
Research Site
Ciudad Autónoma Buenos Aires, 1125
Active, not recruiting
Research Site
Ciudad de Buenos Aires, 1280
Active, not recruiting
Research Site
Ciudad de Buenos Aires, C1118AAT
Active, not recruiting
Research Site
Ciudad de Buenos Aires, C1426ANZ
Active, not recruiting
Research Site
Córdoba, 5000
Active, not recruiting
Research Site
Córdoba, 5001
Active, not recruiting
Research Site
La Plata, 1900
Active, not recruiting
Research Site
Mar del Plata, 7600
Active, not recruiting
Research Site
Salta, A4400EMI
Withdrawn
Research Site
San Juan, 5400
Active, not recruiting
Research Site
San Miguel de Tucumán, 4000
Active, not recruiting
Research Site
San Miguel de Tucumán, T4000IAK
Active, not recruiting
Research Site
Viedma, R8500ACE
Active, not recruiting

Other trials in Argentina

Italy16 sites

Research Site
Bari, 70124
Active, not recruiting
Research Site
Catania, 95126
Active, not recruiting
Research Site
Catanzaro, 88100
Active, not recruiting
Research Site
Florence, 50134
Active, not recruiting
Research Site
Genova, 16132
Active, not recruiting
Research Site
Grosseto, 58100
Active, not recruiting
Research Site
Milan, 20132
Active, not recruiting
Research Site
Milan, 20141
Active, not recruiting
Research Site
Modena, 41125
Active, not recruiting
Research Site
Naples, 80131
Active, not recruiting
Research Site
Naples, 80131
Withdrawn
Research Site
Pisa, 56126
Active, not recruiting
Research Site
Reggio Emilia, 42122
Active, not recruiting
Research Site
Roma, 00168
Active, not recruiting
Research Site
Rozzano, 20089
Active, not recruiting
Research Site
Turin, 10128
Active, not recruiting

Other trials in Italy

Turkey (Türkiye)16 sites

Research Site
Ankara, 06100
Active, not recruiting
Research Site
Ankara, 06200
Active, not recruiting
Research Site
Ankara, 06520
Active, not recruiting
Research Site
Ankara, 06620
Withdrawn
Research Site
Ankara, 6800
Withdrawn
Research Site
Aydin, 9010
Active, not recruiting
Research Site
Bursa, 16059
Withdrawn
Research Site
Dinar, 03400
Active, not recruiting
Research Site
Istanbul, 34010
Withdrawn
Research Site
Istanbul, 34218
Withdrawn
Research Site
Istanbul, 34899
Active, not recruiting
Research Site
Izmir, 35120
Withdrawn
Research Site
Izmir, 35150
Active, not recruiting
Research Site
Izmir, 35530
Active, not recruiting
Research Site
Izmir, 35575
Active, not recruiting
Research Site
Samsun, 55200
Active, not recruiting

Other trials in Turkey (Türkiye)

Mexico15 sites

Research Site
Aguascalientes, 20230
Active, not recruiting
Research Site
Alc. Cuauhtémoc, 06100
Active, not recruiting
Research Site
Colonia Lindavista, 7300
Withdrawn
Research Site
Mérida, 97300
Active, not recruiting
Research Site
México, 14080
Withdrawn
Research Site
México, 14080
Active, not recruiting
Research Site
México, 6700
Active, not recruiting
Research Site
Mexico City, 03310
Active, not recruiting
Research Site
Monterrey, 64460
Withdrawn
Research Site
Monterrey, 64460
Active, not recruiting
Research Site
Monterrey, 64570
Withdrawn
Research Site
San Luis Potosí City, 78250
Withdrawn
Research Site
Toluca, 50180
Active, not recruiting
Research Site
Veracruz, 91900
Active, not recruiting
Research Site
Veracruz, 91910
Active, not recruiting

Other trials in Mexico

Romania15 sites

Research Site
Baia Mare, 430031
Withdrawn
Research Site
Brasov, 500283
Active, not recruiting
Research Site
Cluj-Napoca, 400015
Terminated
Research Site
Cluj-Napoca, 400641
Active, not recruiting
Research Site
Constanța, 900591
Terminated
Research Site
Craiova, 200094
Active, not recruiting
Research Site
Craiova, 200347
Active, not recruiting
Research Site
Craiova, 200385
Active, not recruiting
Research Site
Floreşti, 407280
Active, not recruiting
Research Site
Iași, 700106
Active, not recruiting
Research Site
Oradea, 410167
Withdrawn
Research Site
Piteşti, 110283
Active, not recruiting
Research Site
Sibiu, 550245
Active, not recruiting
Research Site
Timișoara, 300166
Withdrawn
Research Site
Timișoara, 300239
Active, not recruiting

Other trials in Romania

United Kingdom15 sites

Research Site
Brighton, BN2 5BE
Active, not recruiting
Research Site
Burton-on-Trent, DE13 0RB
Active, not recruiting
Research Site
Cambridge, CB2 0QQ
Active, not recruiting
Research Site
Derby, DE22 3NE
Active, not recruiting
Research Site
Edinburgh, EH4 2XU
Active, not recruiting
Research Site
Guildford
Withdrawn
Research Site
Ipswich, IP4 5PD
Active, not recruiting
Research Site
Keighley, BD20 6TD
Withdrawn
Research Site
London, SE1 9RT
Terminated
Research Site
London, SW3 6JJ
Active, not recruiting
Research Site
Manchester, M20 4BX
Active, not recruiting
Research Site
Oxford, OX3 7LJ
Active, not recruiting
Research Site
Peterborough, PE3 9GZ
Withdrawn
Research Site
Stoke-on-Trent, ST4 6QG
Withdrawn
Research Site
Sutton, SM2 5PT
Active, not recruiting

Other trials in United Kingdom

Canada14 sites

Research Site
Barrie, Ontario, L4M 6M2
Active, not recruiting
Research Site
Calgary, Alberta, T2N 4N2
Withdrawn
Research Site
Chicoutimi, Quebec, G7H 5H6
Active, not recruiting
Research Site
Greenfield Park, Quebec, J4V 2H1
Active, not recruiting
Research Site
Kelowna, British Columbia, V1Y 5L3
Active, not recruiting
Research Site
Montreal, Quebec, H1T 2M4
Active, not recruiting
Research Site
Montreal, Quebec, H2X 3E4
Active, not recruiting
Research Site
Montreal, Quebec, H4A 3J1
Active, not recruiting
Research Site
Ottawa, Ontario, K1H 8L6
Withdrawn
Research Site
Saint-Jérôme, Quebec, J7Z 5T3
Active, not recruiting
Research Site
Sault Ste. Marie, Ontario, P6A 0A8
Active, not recruiting
Research Site
Toronto, Ontario, M5G 1X5
Active, not recruiting
Research Site
Windsor, Ontario, N8W 2X3
Active, not recruiting
Research Site
Winnipeg, Manitoba, R3E 0V9
Active, not recruiting

Other trials in Canada

Greece13 sites

Research Site
Athens, 115 28
Withdrawn
Research Site
Athens, 11528
Active, not recruiting
Research Site
Athens, 15123
Active, not recruiting
Research Site
Athens, 18537
Active, not recruiting
Research Site
Chaïdári, 124 62
Active, not recruiting
Research Site
Heraklion, 71110
Active, not recruiting
Research Site
Ioannina, 45500
Active, not recruiting
Research Site
Rio, 265 04
Active, not recruiting
Research Site
Thessaloniki, 546 39
Active, not recruiting
Research Site
Thessaloniki, 54631
Active, not recruiting
Research Site
Thessaloniki, 54645
Terminated
Research Site
Thessaloniki, 54645
Active, not recruiting
Research Site
Thessaloniki, 57001
Active, not recruiting

Other trials in Greece

South Korea13 sites

Research Site
Busan, 48108
Active, not recruiting
Research Site
Daegu, 42601
Active, not recruiting
Research Site
Donggu, 44033
Withdrawn
Research Site
Goyang-si, 10408
Active, not recruiting
Research Site
Jeonnam, 58128
Active, not recruiting
Research Site
Seongbuk-Gu, 2841
Withdrawn
Research Site
Seoul, 03080
Active, not recruiting
Research Site
Seoul, 03722
Active, not recruiting
Research Site
Seoul, 06273
Active, not recruiting
Research Site
Seoul, 06351
Active, not recruiting
Research Site
Seoul, 06591
Active, not recruiting
Research Site
Seoul, 08308
Terminated
Research Site
Seoul, 158-710
Active, not recruiting

Other trials in South Korea

Hungary12 sites

Research Site
Budapest, 1083
Active, not recruiting
Research Site
Budapest, 1106
Withdrawn
Research Site
Budapest, 1115
Active, not recruiting
Research Site
Budapest, 1122
Active, not recruiting
Research Site
Debrecen, 4032
Active, not recruiting
Research Site
Győr, 9024
Active, not recruiting
Research Site
Gyula, 5700
Active, not recruiting
Research Site
Kaposvár, 7400
Active, not recruiting
Research Site
Miskolc, 3526
Active, not recruiting
Research Site
Nyíregyháza, 4400
Active, not recruiting
Research Site
Szekszárd, 7100
Active, not recruiting
Research Site
Szolnok, 5000
Withdrawn

Other trials in Hungary

Poland11 sites

Research Site
Bialystok, 15-027
Active, not recruiting
Research Site
Grudziądz, 86-300
Active, not recruiting
Research Site
Koszalin, 75-581
Active, not recruiting
Research Site
Lodz, 90-302
Active, not recruiting
Research Site
Lublin, 20-718
Active, not recruiting
Research Site
Opole, 45-061
Active, not recruiting
Research Site
Poznan, 61-485
Active, not recruiting
Research Site
Racibórz, 47-400
Active, not recruiting
Research Site
Rzeszów, 35-021
Active, not recruiting
Research Site
Warsaw, 02-781
Active, not recruiting
Research Site
Wieliszew, 05-135
Active, not recruiting

Other trials in Poland

South Africa11 sites, 1 recruiting

Research Site
Bloemfontein, 9301
Active, not recruiting
Research Site
Bloemfontein, 9301
Withdrawn
Research Site
eManzimtoti, 4126
Terminated
Research Site
George, 6529
Withdrawn
Research Site
George, 6529
Active, not recruiting
Research Site
Johannesburg, 2193
Recruiting
Research Site
Johannesburg, 2196
Terminated
Research Site
Pietermaritzburg, 3201
Withdrawn
Research Site
Pretoria, 0084
Withdrawn
Research Site
Pretoria, 31
Active, not recruiting
Research Site
Soweto, 2193
Active, not recruiting

Other trials in South Africa

Colombia10 sites

Research Site
Barranquilla, 080020
Withdrawn
Research Site
Barranquilla, 80020
Withdrawn
Research Site
Bogotá, 110221
Withdrawn
Research Site
Bogotá, 111511
Withdrawn
Research Site
Cali, 760042
Withdrawn
Research Site
Floridablanca, 681004
Withdrawn
Research Site
Medellín, 50030
Withdrawn
Research Site
Montería, 23001
Withdrawn
Research Site
Pereira
Withdrawn
Research Site
Valledupar, 200001
Withdrawn

Other trials in Colombia

Israel10 sites

Research Site
Afula, 1834111
Active, not recruiting
Research Site
Ashdod, 7747629
Active, not recruiting
Research Site
Haifa, 31096
Active, not recruiting
Research Site
Jerusalem, 00000
Active, not recruiting
Research Site
Jerusalem, 9103102
Terminated
Research Site
Kfar Saba, 4428164
Active, not recruiting
Research Site
Nahariya, 22100
Active, not recruiting
Research Site
Ramat Gan, 52621
Active, not recruiting
Research Site
Rehovot, 7661041
Active, not recruiting
Research Site
Tel Aviv, 69710
Withdrawn

Other trials in Israel

Malaysia10 sites

Research Site
George Town, 10350
Active, not recruiting
Research Site
George Town, 10450
Active, not recruiting
Research Site
Johor Bahru, 81100
Active, not recruiting
Research Site
Kota Bharu, 16150
Terminated
Research Site
Kuala Lumpur, 50300
Active, not recruiting
Research Site
Kuala Lumpur, 50450
Active, not recruiting
Research Site
Kuala Lumpur, 50603
Active, not recruiting
Research Site
Kuching, 93586
Active, not recruiting
Research Site
Malacca, 75000
Active, not recruiting
Research Site
Sabak Bernam, 88996
Active, not recruiting

Other trials in Malaysia

Peru10 sites

Research Site
Arequipa, 04001
Withdrawn
Research Site
Arequipa, 4001
Active, not recruiting
Research Site
Arequipa, AREQUIPA01
Active, not recruiting
Research Site
Callao, 7021
Withdrawn
Research Site
La Libertad, 13013
Withdrawn
Research Site
Lima, 0051
Withdrawn
Research Site
Lima, 15076
Active, not recruiting
Research Site
Lima, Lima 32
Terminated
Research Site
Lima, Lima 34
Withdrawn
Research Site
Trujillo
Active, not recruiting

Other trials in Peru

Portugal10 sites

Research Site
Amadora, 2720-276
Active, not recruiting
Research Site
Braga, 4710-243
Active, not recruiting
Research Site
Guimarães, 4835-044
Active, not recruiting
Research Site
Lisbon, 1649-035
Active, not recruiting
Research Site
Lisbon, 1998-018
Active, not recruiting
Research Site
Matosinhos Municipality, 4454-509
Active, not recruiting
Research Site
Porto, 4100-180
Active, not recruiting
Research Site
Porto, 4200-072
Active, not recruiting
Research Site
Porto, 4200-319
Active, not recruiting
Research Site
Vila Nova de Gaia, 4434-502
Active, not recruiting

Other trials in Portugal

Bulgaria9 sites

Research Site
Dobrich, 9300
Active, not recruiting
Research Site
Plovdiv, 4002
Withdrawn
Research Site
Plovdiv, 4004
Active, not recruiting
Research Site
Sofia, 1330
Active, not recruiting
Research Site
Sofia, 1407
Active, not recruiting
Research Site
Sofia, 1431
Withdrawn
Research Site
Sofia, 1606
Withdrawn
Research Site
Sofia, 1784
Terminated
Research Site
Vratsa, 3000
Withdrawn

Other trials in Bulgaria

Chile9 sites

Research Site
Concepción, 4070196
Active, not recruiting
Research Site
La Serena, 1720430
Active, not recruiting
Research Site
Port Montt, 5500243
Active, not recruiting
Research Site
Santiago, 8150215
Active, not recruiting
Research Site
Santiago, 8330032
Active, not recruiting
Research Site
Santiago, 8330336
Active, not recruiting
Research Site
Talca, 3460000
Active, not recruiting
Research Site
Temuco, 4780000
Active, not recruiting
Research Site
Viña del Mar, 2520000
Active, not recruiting

Other trials in Chile

Australia8 sites

Research Site
Birtinya, 4575
Active, not recruiting
Research Site
Concord, 2139
Active, not recruiting
Research Site
Nedlands, 6009
Withdrawn
Research Site
Nedlands, 6009
Active, not recruiting
Research Site
Randwick, 2031
Active, not recruiting
Research Site
Tweed Heads, 2485
Withdrawn
Research Site
Waratah, 2298
Active, not recruiting
Research Site
Wendouree, 3355
Active, not recruiting

Other trials in Australia

Austria8 sites

Research Site
Graz, 8036
Active, not recruiting
Research Site
Kufstein, 6330
Active, not recruiting
Research Site
Ried, 4910
Withdrawn
Research Site
Sankt Veit an der Glan, 9300
Active, not recruiting
Research Site
Vienna, 1090
Active, not recruiting
Research Site
Vienna, 1180
Withdrawn
Research Site
Wein, 1130
Active, not recruiting
Research Site
Wels, 4600
Active, not recruiting

Other trials in Austria

Belgium8 sites, 1 recruiting

Research Site
Brussels, 1090
Active, not recruiting
Research Site
Edegem, 2650
Recruiting
Research Site
Ghent, 9000
Active, not recruiting
Research Site
Leuven, 8500
Active, not recruiting
Research Site
Liège, 4000
Active, not recruiting
Research Site
Ottignies, 1340
Active, not recruiting
Research Site
Wilrijk, 2610
Active, not recruiting
Research Site
Yvoir, 5530
Active, not recruiting

Other trials in Belgium

Serbia8 sites

Research Site
Belgrade, 11000
Active, not recruiting
Research Site
Belgrade, 11010
Active, not recruiting
Research Site
Belgrade, 11080
Active, not recruiting
Research Site
Kamenitz, 21204
Active, not recruiting
Research Site
Kragujevac, 34000
Active, not recruiting
Research Site
Niš, 18000
Active, not recruiting
Research Site
Valjevo, 14000
Active, not recruiting
Research Site
Zrenjanin, 23000
Active, not recruiting

Other trials in Serbia

Taiwan8 sites

Research Site
Hsinchu, 300
Active, not recruiting
Research Site
Kaohsiung City, 82445
Active, not recruiting
Research Site
Taichung, 40447
Withdrawn
Research Site
Tainan, 70403
Active, not recruiting
Research Site
Tainan, 710
Active, not recruiting
Research Site
Taipei, 10002
Active, not recruiting
Research Site
Taipei, 110
Active, not recruiting
Research Site
Taipei, 11259
Active, not recruiting

Other trials in Taiwan

Philippines7 sites

Research Site
Bacolod, 6100
Active, not recruiting
Research Site
Cebu, 6000
Active, not recruiting
Research Site
Iloilo City, 5000
Withdrawn
Research Site
Manila, 1000
Withdrawn
Research Site
Quezon City, 0870
Withdrawn
Research Site
Quezon City, 1101
Terminated
Research Site
Quezon City, 1112
Active, not recruiting

Other trials in Philippines

Thailand7 sites

Research Site
Bangkok, 10400
Active, not recruiting
Research Site
Bangkok, 10700
Active, not recruiting
Research Site
Khon Kaen, 40002
Active, not recruiting
Research Site
Phisanulok, 65000
Active, not recruiting
Research Site
Phitsanulok, 65000
Active, not recruiting
Research Site
Rachathewi, 10400
Active, not recruiting
Research Site
Songkhla, 90110
Active, not recruiting

Other trials in Thailand

Czechia6 sites

Research Site
Hořovice, 268 31
Active, not recruiting
Research Site
Pardubice, 532 03
Active, not recruiting
Research Site
Prague, 140 00
Active, not recruiting
Research Site
Prague, 15006
Withdrawn
Research Site
Pragues, 18081
Withdrawn
Research Site
Příbram, 261 01
Withdrawn

Other trials in Czechia

Netherlands6 sites

Research Site
Dirksland, 3247 BW
Active, not recruiting
Research Site
Geleen, 6162 BG
Active, not recruiting
Research Site
Groningen, 9728 NT
Withdrawn
Research Site
Hoofddorp, 2134 TM
Withdrawn
Research Site
Rotterdam, 3079 DZ
Withdrawn
Research Site
Rotterdam, 3083 AN
Active, not recruiting

Other trials in Netherlands

Georgia5 sites

Research Site
Batumi, 6400
Active, not recruiting
Research Site
Tbilisi, 0179
Active, not recruiting
Research Site
Tbilisi, 112
Active, not recruiting
Research Site
Tbilisi, 160
Withdrawn
Research Site
Tbilisi, 186
Withdrawn

Other trials in Georgia

Singapore4 sites

Research Site
Singapore, 119074
Active, not recruiting
Research Site
Singapore, 228510
Active, not recruiting
Research Site
Singapore, 308433
Active, not recruiting
Research Site
Singapore, 329563
Active, not recruiting

Other trials in Singapore

Vietnam4 sites

Research Site
Hanoi, 100000
Active, not recruiting
Research Site
Ho Chi Minh City, 700000
Active, not recruiting
Research Site
Ho Chi Minh City, 70000
Active, not recruiting
Research Site
Huế, 530000
Withdrawn

Other trials in Vietnam

About this study

Official title: CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence

Read the detailed description

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer who completed definitive locoregional therapy (with or without chemotherapy) and standard adjuvant endocrine therapy (ET) for at least 2 years and up to 5 years. The planned duration of treatment in either arm of the study is 60 months. The eligible patients must have intermediate or high risk of recurrence, as defined by specified clinical and biologic criteria. Prior use of CDK4/6 inhibitors is permitted. The primary endpoint of the study is Invasive breast cancer-free survival (IBCFS) and main secondary endpoints include Invasive disease-free survival (IDFS), Distant relapse-free survival (DRFS), Overall survival (OS), Safety and Clinical Outcome Assessments (COAs).

Patients will be followed for 10 years from randomization of the last patient.

Conditions: Breast Cancer, Early Breast Cancer
Being tested: Camizestrant, Tamoxifen, Anastrozole, Letrozole, Exemestane
Keywords: ER+, HER2-, breast cancer
Medical subject headings: Breast Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

CamizestrantDrug
Also called AZD9833
Camizestrant. Experimental. Administered orally
TamoxifenDrug
Tamoxifen. Comparator. Administered per local approved label
AnastrozoleDrug
Anastrozole. Comparator. Administered per local approved label
LetrozoleDrug
Letrozole. Comparator. Administered per local approved label
ExemestaneDrug
Exemestane. Comparator. Administered per local approved label

Study groups in NCT05774951
Study group	Role	What they receive
Arm A: standard endocrine therapy of investigator´s choice	Active comparator	Continue standard endocrine therapy of investigator's choice (aromatase inhibitors [AI; exemestane, letrozole, anastrozole] or tamoxifen) Receives: Drug: Tamoxifen; Drug: Anastrozole; Drug: Letrozole; Drug: Exemestane
Arm B: camizestrant	Experimental	Camizestrant Receives: Drug: Camizestrant

What is being measured

The primary outcome is the main question the study is designed to answer.

Invasive breast cancer-free survival (IBCFS)
IBCFS is defined as time from randomisation until date of first occurrence of:
- Invasive ipsilateral breast tumour recurrence (invasive IBTR)
- Locoregional invasive breast cancer recurrence
- Distant recurrence
- Invasive contralateral breast cancer
- Death attributable to any cause.
Measured: Up to 10 years

Secondary outcomes (14)

Invasive disease-free survival (IDFS)
IDFS is defined as time from randomisation until date of first occurrence of one of the following events:
- Invasive ipsilateral breast tumor recurrence (invasive IBTR)
- Locoregional invasive breast cancer recurrence
- Distant recurrence
- Invasive contralateral breast cancer
- Second primary non-breast invasive cancer
- Death attributable to any cause.
Measured: Up to 10 years
Distant relapse-free survival (DRFS)
DRFS is defined as time from randomisation until date of first distant recurrence or death from any cause, whichever occurs first.
Measured: Up to 10 years
Overall survival (OS)
OS is defined as time from randomisation until death from any cause.
Measured: Up to 10 years
Incidence and Severity of Adverse Events, with Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI-CTCAE v5.0)
Measured: Until 28 days after the final dose of study treatment (up to 5 years)
Absolute and percent change from baseline in Clinical Laboratory Parameters
Measured: Until 28 days after the final dose of study treatment (up to 5 years)
Absolute and percent change from baseline in Vital Sign Parameters
Measured: Until 28 days after the final dose of study treatment (up to 5 years)
Change from baseline of arthralgia as measured by the EORTC-IL-194 (European Organisation for Research and Treatment of Cancer) item 10. EORTC-IL-194 uses 0 - 4 scale (higher score is worse)
Measured: Until 28 days after the final dose of study treatment (up to 5 years)
Change from baseline of hot flush as measured by the EORTC-IL-194 item 4. EORTC-IL-194 uses 0 - 4 scale (higher score is worse)
Measured: Until 28 days after the final dose of study treatment (up to 5 years)
Change from baseline of vaginal dryness as measured by the EORTC-IL-194 item 15. EORTC-IL-194 uses 0 - 4 scale (higher score is worse)
Measured: Until 28 days after the final dose of study treatment (up to 5 years)
Proportion of patients experiencing each level of symptomatic AEs of arthralgia as measured by the EORTC-IL-194 item 10. EORTC-IL-194 uses 0 - 4 scale (higher score is worse)
Measured: Until 28 days after the final dose of study treatment (up to 5 years)
Proportion of patients experiencing each level of symptomatic AEs of hot flush as measured by the EORTC-IL-194 item 4. EORTC-IL-194 uses 0 - 4 scale (higher score is worse)
Measured: Until 28 days after the final dose of study treatment (up to 5 years)
Proportion of patients experiencing each level of symptomatic AEs of vaginal dryness as measured by the EORTC-IL-194 item 15. EORTC-IL-194 uses 0 - 4 scale (higher score is worse)
Measured: Until 28 days after the final dose of study treatment (up to 5 years)
Change from baseline and TTD (time to deterioration ) of health-related QoL (quality of life) as measured by the 2 global QoL items from the EORTC-QLQ-C30 items 11 and 12. EORTC-QLQ-C30 uses 0 - 4 scale (higher score is worse)
Measured: Until 28 days after the final dose of study treatment (up to 5 years)
Pharmacokinetics (PK)
- Plasma concentrations of camizestrant pre-dose (Ctrough)( trough concentration)
Measured: Until 6 months from treatment start

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

31 Mar 202329 May 2036

First posted20 Mar 2023
Study start31 Mar 2023
Primary completion20 Apr 2027 (estimated)
Study completion29 May 2036 (estimated)

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Publications (1)Papers the sponsor has linked to this study.
Other trials for Breast Cancer, Early Breast CancerStudies of the same condition, open and under way.
More trials run by AstraZenecaThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 3
Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Model description: Patients will be randomised in a 1:1 ratio to one of the following arms: * Arm A: Continue standard ET of investigator's choice (aromatase inhibitors \[AI; exemestane, letrozole, anastrozole\] or tamoxifen) * Arm B: Camizestrant
Masking: None (open label)
Enrolment: 4,300 participants (estimated)

IDs, dates and publications

ClinicalTrials.gov ID: NCT05774951
Sponsor's protocol ID: D8531C00002
Other IDs: 2022-501024-20-00
Acronym: CAMBRIA-1
Status last verified: Oct 2026
First submitted: 16 Feb 2023
Last updated: 13 Oct 2026
Results posted: No
Data monitoring committee: Yes
FDA-regulated drug: Yes
FDA-regulated device: No
Individual data sharing: Yes: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Publications

Hamilton EP, Loibl S, Bachelot T, Gnant M, Niikura N, Park YH, Tolaney SM, Pistilli B, Rastogi P, Saini KS, Gioni I, Johnston S, Nunes R, Quintana A, Stuart M, Syta E, Walding A, Klinowska T, Mayer IA. CAMBRIA-1 & CAMBRIA-2 phase III trials: camizestrant versus standard endocrine therapy in ER+/HER2- early breast cancer. Future Oncol. 2025 Mar;21(7):795-806. doi: 10.1080/14796694.2025.2459548. Epub 2025 Feb 27.
PubMed 40017004

Interested in taking part?

AstraZeneca Clinical Study Information Center

1-877-240-9479

information.center@astrazeneca.com

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See sites and contacts

Active, not recruitingPhase 3
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Early Breast Cancer
Not yet recruiting
PRISM Trial: Partial Breast Versus Whole Breast Radiation in Early Breast Cancer
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Recruiting
Evaluation of the Effect of Regular Physical Exercise in Breast Cancer.
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Not yet recruitingPhase 3
A Study of a Medicine Called Atirmociclib in Combination With Giredestrant in Adult Participants With ER-positive, HER2-negative Early-stage Breast Cancer
Early Breast Cancer, Estrogen Receptor Positive (ER+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-)
RecruitingPhase 3
A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)
Early Breast Cancer

All Breast Cancer, Early Breast Cancer trials